Skip to main content

Assessing the feasibility of MT-011, a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action

Project description

Development of new drug for glaucoma treatment

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Coordinator

MT ACT
Address
66 Rue Du Claous
34190 Cazilhac
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000